▎WuXiEdited by Kant Content Team

SEED Therapeutics Announces Strategic Research Collaboration with Eisai to Discover, Develop, and Commercialize Novel Molecular Glue Protein Degraders Targeting Multiple Undisclosed Neurodegenerative and Oncology TargetsThe total amount of cooperation can reach 1.5 billion US dollars. At the same time, the company announced the completion of the first part of the A-3 round of financing, obtaining 24 million US dollars in funding, with Eisai leading this round of investment.

SEED Therapeutics' Series A-3 financing is expected to further accelerate the clinical development of the company’s internal proprietary programs in cancer and neurodegenerative diseases, and expand its targeted protein degradation platform and pipeline.The companyWill advance its internal potential "best-in-class" oral RBM39 degrader into a Phase 1 clinical trial for biomarker-driven cancer indications starting in 2025.SEED will also advance its internal Tau degrader program for the treatment of Alzheimer's disease.The project is expected to undergo in vivo efficacy testing in 2025 and submit an IND application in 2026.

Seed Therapeutics focuses on leveraging engineered molecular glue degraders to target previously undruggable targets. The company previously reached an up-to-US$800-million R&D collaboration with Eli Lilly to develop innovative protein degradation therapies.